(Q46869277)

English

Immunomodulatory therapy for myelodysplastic syndromes

scientific article published in November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

Immunomodulatory therapy for myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

author name string

Lubomir Sokol

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

Alan F List

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

publication date

1 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

86

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

301-305

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

https://scigraph.springernature.com/pub.10.1532/ijh97.06063

0 references

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinct haematological disorder with deletion of long arm of no. 5 chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Developmental therapeutics for myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/18055335

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1532/IJH97.06063

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18055335

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46869277&oldid=2135345774"